Cardiovascular manifestations of systemic and chronic disease
The cardiac lesions that systemic diseases cause and the clue that links them, from lupus, amyloid and sarcoid to CKD, HIV, carcinoid, neuromuscular disease and cancer therapy.
Tier 2Condition
Written with AI assistance and fact-checked against the sources below. For exam study, not clinical decisions. How notes are made
At a glance
- Many systemic diseases reach the heart. The exam tests the pairing: the disease, its typical cardiac lesion and the clue that links them.
- Think systemic disease when a young patient has conduction disease, when hypertrophy and ECG voltages don't match, when right-sided valves are diseased without a reason, or when heart failure comes with carpal tunnel, neuropathy or proteinuria.
- Management is mostly the standard cardiac treatment plus control of the underlying disease. The traps lie in the exceptions: dialysis for uraemic pericarditis, ICD rather than pacemaker in sarcoid, chemotherapy for AL amyloid.
Loading the rest of the note…
Finished reading?
Sources
- Therapeutic Guidelines: CardiovascularAU/NZTherapeutic Guidelines Limited (eTG complete), current eTG edition (version not verified)
- Government adds two new heart disease treatments on the PBS (tafamidis for ATTR-CM with NYHA class I-II, listed 1 May 2024)AU/NZAustralian Government Minister for Health and Aged Care, 9 May 2024
- 2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease. Eur Heart J 2026European Society of Cardiology and European Renal Association, 2026
- Lyon AR et al. 2022 ESC Guidelines on cardio-oncology. Eur Heart J 2022;43:4229-361European Society of Cardiology, 2022
- Vutrisiran for ATTR-CM, PBAC July 2026 outcome (medicine status)AU/NZPharmaceutical Benefits Scheme, 2026
- PBS Schedule: tafamidis for transthyretin amyloid cardiomyopathy, initial and continuing restrictions (checked November 2026)AU/NZAustralian Government Department of Health, Disability and Ageing, 2026
- Izmirly P et al. Hydroxychloroquine to prevent recurrent congenital heart block in fetuses of anti-SSA/Ro-positive mothers (PATCH). J Am Coll Cardiol 2020;76:292-302Journal of the American College of Cardiology, 2020
- 2025 ESC Guidelines for the management of myocarditis and pericarditisEuropean Society of Cardiology, 2025
- Gillmore JD et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404-12Circulation, 2016
- Grinspoon SK et al. Pitavastatin to prevent cardiovascular disease in HIV infection (REPRIEVE). N Engl J Med 2023;389:687-99New England Journal of Medicine, 2023
- Last updated
- 14 November 2026
What changed
- 14 November 2026 Turnstile bot check on sign-in and signed-out feedback